These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27536683)

  • 1. The Prevalence and Management of Multiple Myeloma-Induced Kidney Disease in China.
    Shi H; Chen Z; Xie J; Chen N
    Kidney Dis (Basel); 2016 Mar; 1(4):235-40. PubMed ID: 27536683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Trends of Renal Impairment in Multiple Myeloma.
    Yadav P; Cook M; Cockwell P
    Kidney Dis (Basel); 2016 Mar; 1(4):241-57. PubMed ID: 27536684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expert consensus for the diagnosis and treatment of patients with renal impairment of multiple myeloma].
    Renal Impairment of Multiple Myeloma Collaborative Study Group
    Zhonghua Nei Ke Za Zhi; 2017 Nov; 56(11):871-875. PubMed ID: 29136724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.
    Dimopoulos MA; Sonneveld P; Leung N; Merlini G; Ludwig H; Kastritis E; Goldschmidt H; Joshua D; Orlowski RZ; Powles R; Vesole DH; Garderet L; Einsele H; Palumbo A; Cavo M; Richardson PG; Moreau P; San Miguel J; Rajkumar SV; Durie BG; Terpos E
    J Clin Oncol; 2016 May; 34(13):1544-57. PubMed ID: 26976420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current treatments for renal failure due to multiple myeloma.
    Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Pharmacother; 2016 Nov; 17(16):2165-2177. PubMed ID: 27646819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
    Dimopoulos MA; Terpos E; Chanan-Khan A; Leung N; Ludwig H; Jagannath S; Niesvizky R; Giralt S; Fermand JP; Bladé J; Comenzo RL; Sezer O; Palumbo A; Harousseau JL; Richardson PG; Barlogie B; Anderson KC; Sonneveld P; Tosi P; Cavo M; Rajkumar SV; Durie BG; San Miguel J
    J Clin Oncol; 2010 Nov; 28(33):4976-84. PubMed ID: 20956629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib-Based Chemotherapy with Autologous Stem Cell Transplantation for Monoclonal Gammopathy of Renal Significance: A Case Report and Literature Review.
    Huang J; Sun C; Su H; Zhang C; Xiong J
    Kidney Blood Press Res; 2019; 44(4):858-869. PubMed ID: 31352451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
    Ho PJ; Moore EM; McQuilten ZK; Wellard C; Bergin K; Augustson B; Blacklock H; Harrison SJ; Horvath N; King T; Mollee P; Quach H; Reid C; Rosengarten B; Walker P; Wood EM; Spencer A
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e415-e424. PubMed ID: 31208889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative Impact of Borderline Creatinine Concentration and Glomerular Filtration Rate at Baseline on the Outcome of Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplant.
    Waszczuk-Gajda A; Małyszko J; Vesole DH; Feliksbrot-Bratosiewicz M; Skwierawska K; Krzanowska K; Kobylińska K; Biecek P; Snarski E; Rodziewicz-Lurzyńska A; Kozłowski P; Stefaniak A; Drozd-Sokołowska J; Ziarkiewicz M; Vyas P; Boguradzki P; Mądry K; Biliński J; Tomaszewska A; Maciejewska M; Urbanowska E; Blajer B; Król M; Król M; Zborowska H; Jurczyszyn A; Dwilewicz-Trojaczek J; Jedrzejczak WW; Basak GW
    Transplant Proc; 2020 Sep; 52(7):2186-2192. PubMed ID: 32222395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Clinical Presentation and Management of Systemic Light-Chain Amyloidosis in China.
    Huang XH; Liu ZH
    Kidney Dis (Basel); 2016 Apr; 2(1):1-9. PubMed ID: 27536686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
    Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K
    Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.
    Bridoux F; Chen N; Moreau S; Arnulf B; Moumas E; Abraham J; Desport E; Jaccard A; Fermand JP
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):173-82. PubMed ID: 27286995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience.
    Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A
    Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
    Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
    Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
    Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
    Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study.
    Antlanger M; Dust T; Reiter T; Böhm A; Lamm WW; Gornicec M; Willenbacher E; Nachbaur D; Weger R; Rabitsch W; Rasoul-Rockenschaub S; Worel N; Lechner D; Greinix H; Keil F; Gisslinger H; Agis H; Krauth MT
    BMC Cancer; 2018 Oct; 18(1):1008. PubMed ID: 30342509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the RIFLE criteria for the diagnosis of Acute Kidney Injury; a retrospective study in South-Western Ghana.
    Ephraim RKD; Darkwah KO; Sakyi SA; Ephraim M; Antoh EO; Adoba P
    BMC Nephrol; 2016 Jul; 17(1):99. PubMed ID: 27460991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current treatments for renal failure due to multiple myeloma.
    Kastritis E; Terpos E; Dimopoulos MA
    Expert Opin Pharmacother; 2013 Aug; 14(11):1477-95. PubMed ID: 23705905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
    Zannetti BA; Zamagni E; Santostefano M; De Sanctis LB; Tacchetti P; Mancini E; Pantani L; Brioli A; Rizzo R; Mancuso K; Rocchi S; Pezzi A; Borsi E; Terragna C; Marzocchi G; Santoro A; Cavo M
    Am J Hematol; 2015 Jul; 90(7):647-52. PubMed ID: 25858483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.